A recent study compared the effectiveness of stereotactic ablative body radiotherapy with conventional full fractionated radiotherapy in prolonging time to local failure in patients with inoperable stage I non-small cell lung cancer. READ MORE
Patients with advanced, EGFR-mutant non-small cell lung cancer live almost twice as long without disease progression after initial treatment with an EGFR inhibitor compared with standard of care tyrosine kinase inhibitor therapy.
A recent comparison between commonly-used therapies for untreated, advanced ALK-positive NSCLC demonstrated superior efficacy and lower toxicity for one therapy.
Researchers have identified a new outcome measurement that should be considered a practical clinical end point for early evaluation in emerging therapies for non-small cell lung cancer.
Researchers compared long-term health-related quality of life in patients with advanced lung or gastrointestinal cancer after administration of either chemotherapy or placebo.
Research in Review
A blood-based proteomic test offers prognostic information and optimal second-line treatment guidance for patients with squamous cell carcinoma of the lung.
Analysis of high-risk lung cancer screening shows that screening is cost-effective and may offer cost savings if noncurative treatment costs continue to rise.
A new prognostic model for lung cancer with brain metastases uses histology, mutations, number of metastases, performance status, and age to accurately predict survival outcomes in patients.
Results of a recent study offer insight into the effects of shifting treatment patterns of non-small cell lung cancer on patient outcomes, and for furthering community oncology benchmark initiatives.